AFC-HD AMS LIFE SCIENCE CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 846 JPY | 0.00% |
|
-1.74% | +5.75% |
| Sales 2022 | 23B 148M | Sales 2023 | 25.58B 164M | Capitalization | 11.12B 71.49M |
|---|---|---|---|---|---|
| Net income 2022 | 735M 4.72M | Net income 2023 | 1.1B 7.08M | EV / Sales 2022 | 0.76 x |
| Net Debt 2022 | 6.76B 43.43M | Net Debt 2023 | 8.35B 53.7M | EV / Sales 2023 | 0.76 x |
| P/E ratio 2022 |
14.8
x | P/E ratio 2023 |
10.1
x | Employees | 878 |
| Yield 2022 |
3.9% | Yield 2023 |
3.45% | Free-Float | 63.51% |
More Fundamentals
* Assessed data
More news
| 1 week | -1.74% | ||
| Current month | -9.03% | ||
| 1 month | -11.69% | ||
| 3 months | -7.24% | ||
| 6 months | +10.44% | ||
| Current year | +5.75% |
1 week
835.00
864.00
1 month
835.00961.00
Current year
801.00968.00
1 year
753.00968.00
3 years
668.001 557.00
5 years
517.001 557.00
10 years
517.001 557.00
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 55 | 00-05-31 | |
Takehiko Asayama
CHM | Chairman | 55 | 01-03-31 |
Kazunori Takada
ADM | Chief Administrative Officer | 56 | 07-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takehiko Asayama
CHM | Chairman | 55 | 01-03-31 |
| Director/Board Member | 55 | 00-08-31 | |
Naoya Umino
CTO | Chief Tech/Sci/R&D Officer | 54 | 98-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 846 | 0.00% | 29 500 |
| 24-04-24 | 846 | +0.24% | 31,600 |
| 24-04-23 | 844 | -0.12% | 46,300 |
| 24-04-22 | 845 | +0.36% | 189,200 |
| 24-04-19 | 842 | -2.21% | 81,000 |
Delayed Quote Japan Exchange, April 25, 2024 at 02:00 am EDT
More quotes
AFC-HD AMS Life Science Co Ltd is a Japan-based company mainly engaged in the development of the healthcare business and the pharmaceutical business. The Company is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The Company operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The Company is also engaged in the management of restaurants through subsidiary.
Sector
Food Processing
Calendar
2024-07-10
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +5.75% | 76.22M | |
| +6.96% | 7.69B | |
| +5.49% | 6.24B | |
| -8.63% | 3.65B | |
| -13.28% | 3.43B | |
| -15.49% | 1.16B | |
| +10.65% | 961M | |
| -39.71% | 918M | |
| -18.47% | 841M | |
| -17.52% | 790M |
- Stock Market
- Equities
- 2927 Stock
